Open Access
| Issue |
BIO Web Conf.
Volume 142, 2024
2024 International Symposium on Agricultural Engineering and Biology (ISAEB 2024)
|
|
|---|---|---|
| Article Number | 03006 | |
| Number of page(s) | 6 | |
| Section | Microbial Engineering and Biomedical Exploration | |
| DOI | https://doi.org/10.1051/bioconf/202414203006 | |
| Published online | 21 November 2024 | |
- Yang TY. (2018) A study of the efficacy of febuxostat in the treatment of gout with hyperuricemia in 45 cases. World Latest Medicine Information. 18:73+86. [Google Scholar]
- Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C. (2014) An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 6:679-86. [CrossRef] [PubMed] [Google Scholar]
- Yan HB, Chen SS, Cheng HR. (2020) Allopurinol versus febuxostat for hyperuricemia. Modern Diagnosis And Treatment. 31:3744-3746. [Google Scholar]
- Mo SQ, Xu BJ, Li YL, Hou ZZ, Lin L. (2022) Comparison of the efficacy of benzbromarone and febuxostat in the treatment of gout complicated with hyperuricemia. Journal of China Prescription Drug. 20:46-48. [Google Scholar]
- Zhang S, Xu T, Shi Q, Li S, Wang L, An Z, Su N. (2021) Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis. Front Med (Lausanne). 8:698437. [CrossRef] [Google Scholar]
- Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X, Liu H, Peng Y, Wang J, Lin J, Ji H, Liu B, Lu Y, Liu P, Zhang Y, Ji Q. (2015) A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis. 18(6):669-78. [CrossRef] [Google Scholar]
- Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. (2011) Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 38:1385-1389. [CrossRef] [PubMed] [Google Scholar]
- Zhao PZ. (2021) Efficacy and safety of febuxostat and allopurinol in the treatment of patients with gout and hyperuricemia. Clinical Research. 29:59-60. [Google Scholar]
- Zhang L. (2020) Comparison of the clinical study of febuxostat and allopurin tablets in the treatment of hyperuricemia with gout. World Journal of Complex Medicine.5:177-179. [Google Scholar]
- Huang YY, Ye Z, Gu SW, Jiang ZY, Zhao L.(2020) The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout. J Int Med Res. 48:300060520902950. [CrossRef] [PubMed] [Google Scholar]
- Liu QY, Qi GD, Chen X.(2018) Effect of febuxostat on blood rheology and platelet activation in patients with gout and hyperuricemia. Basic & Clinical Medicine.38:1568-1571 [Google Scholar]
- Desideri G, Rajzer M, Gerritsen M, Nurmohamed MT, Giannattasio C, Tausche AK, Borghi C. (2022) Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. Eur Heart J Cardiovasc Pharmacother. 8:236-242. [CrossRef] [PubMed] [Google Scholar]
- Zhang W, Xie WC, Xu JE, Liu W, Zhang XJ. (2016) Effects of febuxostat on the seum sICAM-1, ET-1 and uric acid levels of patients with gout and hyperuricemia. Progress In Modern Biomedicine. 16:5303-5305. [Google Scholar]
- Wang HR, Liang HD, Liu QL. (2019) Comparison of the clinical efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. Journal of China Prescription Drug. 17:115-116. [Google Scholar]
- Zhang XY, Xu L, Li SD (2019) Comparison of effect of febuxostat and allopurinol in the treatment of gout complicated with hyperuricemia. Chinese Journal of Primary Medicine and Pharmacy. 25:738-740. [Google Scholar]
- Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 353:2450-2461. [CrossRef] [PubMed] [Google Scholar]
- Zhang T, Wang F, Zhang WT, Bai Y (2017) Effect ofcomplicated with hyperuricemia febuxostat on the serum levels of uric acid, TNF-a and sICAM in patients with gout. Journal of Guangxi Medical University.34:1224-1226. [Google Scholar]
- Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52:916-923. [CrossRef] [PubMed] [Google Scholar]
- Sun SS. (2020) Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: a comprehensive network meta-analysis of randomized controlled trials and the prognostic role of MYBL2 in clear cell renal cell carcinoma. China Medical University. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.